Company news
Elutia, Inc. (NASDAQ:ELUT) news
Every Elutia, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Sur...
August 13, 2026
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
July 31, 2026
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NX...
July 16, 2026
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
June 11, 2026
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
May 14, 2026
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
April 30, 2026
Elutia to Present at Sidoti’s Small-Cap Virtual Investor Conference March 18-19
March 17, 2026
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
March 13, 2026
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
March 11, 2026
Elutia Regains Compliance with Nasdaq Listing Requirements
March 4, 2026
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast S...
March 2, 2026
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
February 25, 2026
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™
February 18, 2026
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
January 12, 2026
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
January 9, 2026
Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Fu...
November 6, 2025
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
October 23, 2025
Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21
October 14, 2025
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors
October 10, 2025
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
October 1, 2025
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
September 16, 2025
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
September 9, 2025
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
September 4, 2025
Elutia to Participate in Upcoming Investor Conferences
August 27, 2025
Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
August 14, 2025
Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
July 31, 2025
Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award
July 31, 2025
New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices
July 1, 2025
Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards
June 26, 2025
Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method
May 28, 2025
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
May 8, 2025
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio
May 1, 2025
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
May 1, 2025
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29
April 22, 2025
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice
April 21, 2025
Elutia Confirms No Material Impact from Global Tariffs
April 14, 2025
EluPro™ Named as 2025 Edison Award Winner
April 4, 2025
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes
April 2, 2025
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
March 27, 2025
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope
March 25, 2025
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full C...
March 6, 2025
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025
February 20, 2025
Elutia Announces $15.0 Million Registered Direct Offering
February 3, 2025
Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand
January 14, 2025
Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners
January 6, 2025
Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.
December 2, 2024
Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025
November 14, 2024
Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024
October 29, 2024
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
October 23, 2024
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Impla...
September 18, 2024